Resources>Citations Database>Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy

Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy

Biointron 2022-10-10

Authors: Zhen-Hua Wu, Na Li 1, Zhang-Zhao Gao, Gang Chen, Lei Nie, Ya-Qiong Zhou, Mei-Zhu Jiang, Yao Chen, Juan Chen, Xiao-Fen Mei, Feng Hu and Hai-Bin Wang

Journal: Cancers

PubMed ID: 36230887

DOI: https://doi.org/10.3390/cancers14194964

Products & Services: Human IgG1 isotype control was expressed by Biointron Human IgG1 isotype control was expressed by Biointron

Recommended Articles
MRNA Profiling Involved in Triggering of STAT1 with Regulatory Involvement of IRF7, PTPRF, and miR-145p in Patients Suffering from Gall Bladder Carcinoma
Nov 25, 2025
Droplet Squeeze Microfluidic Platform for Generating Extracellular Vesicle Hybrids for Drug Delivery

Droplet Squeeze Microfluidic Platform for Generating Extracellular Vesicle Hybri……

Aug 07, 2025
Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma

Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of ……

Aug 01, 2025
Inhibition of long-lived plasma cells, a critical role for Telitacicept treatment to systemic lupus erythematosus

Inhibition of long-lived plasma cells, a critical role for Telitacicept treatmen……

Jul 30, 2025

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.